Latest Breaking News On - Division of lymphoma - Page 1 : comparemela.com

Dr Phillips on the Safety and Efficacy of Glofitamab in Relapsed/Refractory MCL

Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.

City of Hope's Dr Tycel Phillips Discusses Promise of Glofitamab in Heavily Pretreated MCL

Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab.

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

City of Hope Shares Promising Stem Cell and Blood Cancer Data at ASCO 2024

Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor Exposure

Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.